{"id":"abr-215050-tasquinimod","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2107784","moleculeType":"Small molecule","molecularWeight":"406.36"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tasquinimod works by binding to S100A9, a protein involved in the regulation of immune responses. This binding leads to the activation of immune cells, such as macrophages and T cells, which can help to fight cancer cells. By modulating the immune system in this way, tasquinimod may help to slow the progression of cancer.","oneSentence":"Tasquinimod is a quinoline-3-carboxamide derivative that modulates the immune system by targeting the S100A9 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:23.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"}]},"trialDetails":[{"nctId":"NCT06327100","phase":"PHASE1, PHASE2","title":"Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-01","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis","enrollment":33},{"nctId":"NCT04405167","phase":"PHASE1","title":"Tasquinimod for the Treatment of Relapsed or Refractory Myeloma","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT06605586","phase":"PHASE1, PHASE2","title":"Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2025-02-20","conditions":"Myelofibrosis","enrollment":20},{"nctId":"NCT02159950","phase":"PHASE2","title":"Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2015-01","conditions":"Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":2},{"nctId":"NCT02057666","phase":"PHASE3","title":"Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Ipsen","startDate":"2014-01","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":146},{"nctId":"NCT01732549","phase":"PHASE2","title":"A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy","status":"TERMINATED","sponsor":"Ipsen","startDate":"2013-01","conditions":"Metastatic Castrate Resistant Prostate Cancer","enrollment":144},{"nctId":"NCT01743469","phase":"PHASE2","title":"A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers","status":"COMPLETED","sponsor":"Ipsen","startDate":"2012-12","conditions":"Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer","enrollment":201},{"nctId":"NCT01513733","phase":"PHASE1","title":"The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2012-01","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT02396368","phase":"PHASE1","title":"A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-03","conditions":"Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)","enrollment":""},{"nctId":"NCT00560482","phase":"PHASE2","title":"Efficacy Study of ABR-215050 to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Active Biotech AB","startDate":"2007-12","conditions":"Prostate Cancer","enrollment":206},{"nctId":"NCT01234311","phase":"PHASE3","title":"A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Active Biotech AB","startDate":"2011-03","conditions":"Prostate Cancer","enrollment":1245},{"nctId":"NCT01048203","phase":"PHASE1","title":"A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects","status":"COMPLETED","sponsor":"Active Biotech AB","startDate":"2009-01","conditions":"Healthy","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":101,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABR-215050, tasquinimod","genericName":"ABR-215050, tasquinimod","companyName":"Active Biotech AB","companyId":"active-biotech-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tasquinimod is a quinoline-3-carboxamide derivative that modulates the immune system by targeting the S100A9 protein. Used for Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}